Navigation Links
Aegerion Pharmaceuticals, Inc. adds Peter Garrambone to Board of Directors, Secures Additional Capital for Clinical Trials
Date:9/4/2008

Data Announcements Remain on Schedule with Two Abstracts Accepted for

Presentation, and Large Clinical Data Release in November 2008

BRIDGEWATER, N.J., Sept. 4 /PRNewswire/ -- Aegerion Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the treatment of cardiovascular and metabolic disease, today announced the appointment of Peter L. Garrambone, Jr. to the Company's board of directors.

Peter Garrambone's career includes more than 50 pharmaceutical transactions executed during his 24-year tenure at Pfizer, where he was a senior vice president of Corporate Strategic Planning. At Pfizer, Mr. Garrambone led the company's corporate business development and strategic planning efforts. Most recently, Mr. Garrambone was senior vice president of Business Development for Reliant Pharmaceuticals, which was sold to GlaxoSmithKline for $1.65 billion in the fall of 2007.

"We are fortunate that Peter is joining the board of directors. His extensive strategic and licensing transaction expertise will be invaluable as the company continues the pursuit of its strategic plan with the availability of its important clinical data in November of this year," said David Scheer, Chairman and Co-Founder of Aegerion.

In furtherance of its strategic plan, the Company announced that it had secured additional funding from investors to support ongoing and future clinical trials. The Company will be presenting an abstract at both the American Association for the Study of Liver Disease and American Heart Association Meetings in the fourth quarter of 2008.

Aegerion anticipates receiving the results of three Phase II trials on AEGR 733 before the end of 2008. These trials, comprised of more than 460 patients, are designed to explore the efficacy, safety and tolerability of AEGR 733, Aegerion's lead compound. A Phase III study of AEGR 733 in the orphan population of homozygous familial hypercholesterolemic patients is currently underway.
'/>"/>

SOURCE Aegerion Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
2. Rib-X Pharmaceuticals, Inc. Announces Recent and Upcoming Presentations at Scientific Conferences
3. Meditrina Pharmaceuticals, Inc. Opens Investigational New Drug (IND) Application for Phase IIb Clinical Trial With MPI-676 in Endometriosis
4. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
5. Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytrens Contracture
6. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
7. Jazz Pharmaceuticals, Inc. Completes Enrollment in First of Two Phase III Clinical Trials of Sodium Oxybate to Treat Fibromyalgia
8. Arena Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of Drug Candidate Under Partnership with Taisho Pharmaceutical Co., Ltd.
9. Alseres Pharmaceuticals, Inc. to Address a Congressional Briefing on Paralysis Research and the Spinal Cord Injury Community at Working 2 Walk in Washington, DC, April 13-15, 2008
10. Lotus Pharmaceuticals, Inc. Achieves Significant Milestones in the Development of Isosorbide Mononitrate Sustained Release Tablets
11. Jazz Pharmaceuticals, Inc. Announces Receipt of FDA Orphan Drug Designation for Recurrent Acute Repetitive Seizures Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2008)... REINACH, Switzerland, November 20 /PRNewswire... that the Anti-infective Drugs Advisory Committee ...s voted 17 to 2 against the,approval of intraveno...t for,the treatment of patients with complicated ...uding those caused by methicillin-resistant Staphy...
(Date:11/20/2008)... LA JOLLA, Calif., Nov. 20 /PRNewswire-FirstCall/ ... DSKA), announced today that it has submitted its,...r review under a Special,Protocol Assessment (SPA...tion,(FDA). , Subject to securing an agree...ngle, prospective, double-blind, placebo-controlle...
(Date:11/20/2008)... BOSTON, Nov. 20 PAREXEL...ading global biopharmaceutical services provider, ...ma, Peru to provide regulatory consulting and clin...he Peru office, PAREXEL now has locations througho...in America, which also include Argentina, Brazil, ...
(Date:11/19/2008)... THOUSAND OAKS, Calif., Nov. 19 /PRNewswire-FirstC...he Takeda Oncology Company, a subsidiary of,Taked...y announced that,enrollment in the Phase 3 MONET1...ion with paclitaxel and carboplatin for the first-...ncer (NSCLC) has been temporarily suspended,follo...
Breaking Medicine Technology:Arpida Comments on FDA's Anti-infective Drugs Advisory Committee Outcome 2Arpida Comments on FDA's Anti-infective Drugs Advisory Committee Outcome 3Arpida Comments on FDA's Anti-infective Drugs Advisory Committee Outcome 4Duska Therapeutics Applies for Phase 3 Special Protocol Assessment 2Duska Therapeutics Applies for Phase 3 Special Protocol Assessment 3Duska Therapeutics Applies for Phase 3 Special Protocol Assessment 4PAREXEL Strengthens Leading Presence in Latin America With a New Location in Peru 2PAREXEL Strengthens Leading Presence in Latin America With a New Location in Peru 3PAREXEL Strengthens Leading Presence in Latin America With a New Location in Peru 4Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 2Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 3Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 4Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 5Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 6Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 7High Blood Pressure May Heighten Effects of Alzheimers Disease 934 1High Blood Pressure May Heighten Effects of Alzheimers Disease 934 2Transporters may help delay diabetes related retinal damage 7116 1Transporters may help delay diabetes related retinal damage 7116 2Transporters may help delay diabetes related retinal damage 7116 3Nanotechnology and the media 3A The inside story 1364 1Nanotechnology and the media 3A The inside story 1364 2Promising Data ATIR Studies Presented by NIH Investigators 1980 1Promising Data ATIR Studies Presented by NIH Investigators 1980 2
(Date:11/21/2008)... The Providence Service,...t Craig A. Norris, the Company,s,Chief Operating ... of,Directors. Mr. Norris, appointment fills the...even I. Geringer and returns the board to six memb...of the Board. , Mr. Norris, age 41, has bee...
(Date:11/21/2008)...roved effective against Lennox-Gastaut syndrome ,...new drug called Banzel (rufinamide) has been appro... of epilepsy called Lennox-Gastaut syndrome, the U... , The approval was based on results of a four-... to 30. Compared to patients who took a placebo, t...
(Date:11/21/2008).... 21 New research at W...okeless, spitless tobacco product aimed at young a...nd that RJ Reynolds, Camel Snus - touted as a soci...s surprisingly high levels of nicotine. , , ...r snuff products," said Bruce Adkins of the state ...
(Date:11/21/2008)...1 U.S. News & World...urance (NCQA) ranked BlueChoice(R) HealthPlan of S...ealth Plans(TM), published in U.S. News & Worl...ed annual ranking ranks the nation,s best health p...n and NCQA accreditation scores. NCQA and U.S. New...
Breaking Medicine News(10 mins):Health News:Craig A. Norris Appointed to Providence Service Corporation Board of Directors 2Health News:Craig A. Norris Appointed to Providence Service Corporation Board of Directors 3Health News:FDA Approves New Drug for Severe Epilepsy 2Health News:Experts Say New Tobacco Product Targets Young Adults 2Health News:Experts Say New Tobacco Product Targets Young Adults 3Health News:BlueChoice HealthPlan Ranks in Top Third of America's Best Health Plans 2
...esticides and solvents can further lower fertility...udy shows these chemicals may worsen the effect of...infertility. The authors stress the findings shoul... involved a selected population of infertile men, ...
...communication has always been an effective utility...eo disc is helping patients make important decisio...ld you what treatment to have are long gone. Patie...aking process.// But sometimes this is difficult, ...
...e era where one fights battle towards eternity and...ality and morbidity indicators preclude the exista... result of such on going research , Dr. Simona Gia... Sanita, Rome, and colleagues from the MATISS Proj...
...orks better than massage as a treatment for chroni...ther therapies when used over long periods.That's ...into the effectiveness of the complementary medici... needles into special sites in the nervous system....
Other Medicine News:
CleanBox DNA workstation with two 254nm UV lambs & 12-hr timer, 90cm (36-inch)width, single door, 115V (w/crating)
...ing of tube racks. Its camera-based vision system ... per rack, making it ideal for use in automated se... rack to be read automatically and can be easily a...prevents a rack from being read in the wrong orien...
Polypropylene workbench top with powder-coated steel legs. Height is adjustable from 25"-34". Available in hundreds of sizes and configurations. Accessories include shelves, drawers, light fixtures a
Perforated or Rod Top, Free Standing or Wall Mounted, Storage Cubby Optional, Polypropylene Construction
Medicine Products: